Oregon Health & Science University (OHSU): Gleevec, the Targeted Cancer Pill, Delivers More Good News to Patients

PORTLAND, Ore. – Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia. “Data at this weekend’s meeting continues to show how much Gleevec has completely changed the outlook for so many, many patients facing cancer,” said Brian Druker, M.D., director of the OHSU Cancer Institute.